Skip to content
Review

Germline predisposition and the pattern of breast cancer metastasis.

Sep 2026 · Cancer Research · 0 citations
Medicine

TL;DR

The synthesis of data from mouse models and human-derived materials supports a speculative model where the crosstalk between BC cells and the microenvironment defines the metastasis pattern in carriers of GPVs in BCSGs.

Abstract

More than three decades have passed since the identification of BRCA1 as the first breast cancer susceptibility gene (BCSG). Since then, substantial progress has been made in pinpointing BCSGs and estimating the associated risk of developing BC. Simultaneously, new challenges and open questions have also emerged, such as the potential associations between BCSGs and metastasis in BC patients. In this review, we discuss available data from clinical and experimental studies assessing the association between germline pathogenic variants (GPVs) in BCSGs and metastasis pattern. To help guide future studies addressing the current knowledge gaps, the review outlines clinical outcomes and four variables to be considered: 1) age and ethnicity; 2) clinical, molecular, and pathological characteristics; 3) treatment response; and 4) the specificity of BSCG variants. The synthesis of data from mouse models and human-derived materials supports a speculative model where the crosstalk between BC cells and the microenvironment defines the metastasis pattern in carriers of GPVs in BCSGs. An experimental framework is proposed for testing this model in future studies that could parallel comprehensive clinical studies addressing the outlined clinical outcomes and variables.

View source

Similar papers

Review Open access Sep 2026

Liquid biopsy: a new window on the BRCA genes

Beyond the attractive potential to surrogate the tumor tissue testing, to overcome the cancer spatial and temporal heterogeneity, and to monitor the tumor mutational profile over time, accurately detecting all clinically relevant BRCA genetic variants and epigenetic modifications using LB remains technically challengin...

L. Incorvaia, V. Gristina, F. Pepe et al. · 0 citations
Review Open access Aug 2026

Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review)

Focusing on acquired resistance as a core bottleneck in precision therapy, mechanisms underlying anti-Human Epidermal Growth Factor Receptor 2 (HER2) resistance and primary/secondary resistance to immune checkpoint inhibitors (ICIs) were systematically dissected, while also addressing immune-related adverse events and...

Shu-Jing Xia, Xiumei Zhang, Li-Zhong Tang et al. · 0 citations
Review Open access Sep 2026

Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer

ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical locatio...

Nisha Manav, Akanksha Kashyap, Lakshay Malhotra et al. · 0 citations
Sep 2026

Abstract IA01: New frontiers in childhood cancer predisposition: Harnessing genomics for early detection and tumor interception

The challenges and opportunities for early cancer detection and interception in the context of pediatric cancer predisposition are exemplified by the paradigm cancer predisposition disorder, Li-Fraumeni syndrome. More than 85% of patients with Li-Fraumeni Syndrome harbour germline TP53 mutations. The genetic and phen...

David Malkin · 0 citations

The role of SLC7A11 in regulating breast cancer brain metastasis

SLC7A11 is identified as a non-canonical regulator of ECM/integrin-mediated FAK survival signaling in brain metastatic breast cancer cells, indicating that FAK signaling contributes to BCBM tumor maintenance and that it's inhibition can effectively suppress tumor growth.

Kevin Michael Hughley, Mauricio J. Reginato · 0 citations
#data science Review Open access Oct 2026

The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review

Intratumor heterogeneity (ITH), the coexistence of diverse subclones within a single tumor, may pose a major challenge to effective chemotherapy in breast cancer. This cellular diversity contributes to treatment failure, residual disease, and early relapse by enabling tumor adaptation and therapeutic resistance. Althou...

Aria Dianati, Andre Dekker, A. Wesselius et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.